Are Drug-Eluting Stents Cost-Effective?
نویسندگان
چکیده
منابع مشابه
Will drug-eluting stents bankrupt the healthcare system? Are Drug-Eluting Stents Cost-Effective? It Depends on Whom You Ask
Since their commercial introduction in 2003, drugeluting stents (DES) have rapidly altered the management of coronary artery disease. Before their development, the percutaneous management of coronary artery disease was performed predominantly by implantation of bare metal stents (BMS) made of either surgical stainless steel or metal alloys. Although such stents represented a considerable advanc...
متن کاملAre drug-eluting stents cost-effective? It depends on whom you ask.
Since their commercial introduction in 2003, drugeluting stents (DES) have rapidly altered the management of coronary artery disease. Before their development, the percutaneous management of coronary artery disease was performed predominantly by implantation of bare metal stents (BMS) made of either surgical stainless steel or metal alloys. Although such stents represented a considerable advanc...
متن کاملAll drug-eluting stents are equal, but some drug-eluting stents are more equal than others.
b t r t a s S g S d s b r a p a T v v p he first battle fought by drug-eluting stents (DES) was ith bare-metal stents. The 2 DES approved by the U.S. ood and Drug Administration, sirolimus drug-eluting tents (S-DES) and paclitaxel drug-eluting stents (P-DES), howed superiority in significantly reducing restenosis rates nd target lesion revascularization rates compared with are-metal stents in a...
متن کاملDrug-eluting stents: cost versus clinical benefit.
The publication in January 2001 of the first-in-man results showing zero restenosis after sirolimus-eluting stent implantation produced enormous excitement in the cardiological community.1 The long-awaited tool—a safe, restenosis-proof, easy-to-use stent—had been found. It was not too long thereafter that paclitaxel-eluting stents also demonstrated their capability to decrease restenosis. Today...
متن کاملAre Drug Eluting Stents Worth Triple Therapy?
A pproximately 8% patients undergoing percutaneous coronary intervention are on anticoagulation, which creates difficult choices regarding stent type and antiplatelet use. Drug eluting stents (DES) are usually preferred over bare metal stents (BMS) because of less restenosis and fewer repeat revascularization procedures. However, DES require a longer duration of dual antiplatelet therapy to min...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation
سال: 2006
ISSN: 0009-7322,1524-4539
DOI: 10.1161/circulationaha.105.546010